Clinical trial · Interventional
A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma
An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma
NCT03514407CI-TRIAL-00096684terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Strategic Business Decision
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and preliminary antitumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed Ewing Sarcoma | Ewing Sarcoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| INCB059872 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- INCB059872
- description
- INCB059872
- interventionNames
- Drug: INCB059872
Primary outcomes (1)
- measure
- Number of adverse events
- timeFrame
- Screening through 30 days after last dose of study treatment, up to approximately 6 months.
- description
- Defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of a drug in humans, whether or not considered drug-related.
Secondary outcomes (5)
- measure
- Objective response rate
- timeFrame
- Up to approximately 6 months.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of Ewing sarcoma and have progressed on or after standard therapies. * Must not be a candidate for potentially curative therapy or standard-of-care approved therapy. * Measurable disease by computed tomography or magnetic resonance imaging based on RECIST 1.1 as determined by site radiology. * Eastern Cooperative Oncology Group performance status 0 to 2. * Willingness to avoid pregnancy or fathering children. Exclusion Criteria: * Receipt of anticancer medications, anticancer therapies, or investigational drugs within protocol-defined intervals before the first administration of study drug. * Must have recovered (≤ Grade 2 or at pretreatment baseline) from adverse events (AEs) from previously administered therapies except for stable chronic toxicities (≤ Grade 2) not expected to resolve. * Untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed. * Prior radiotherapy within 2 weeks of study treatment. A 1-week washout period is permitted for palliative radiation to non-CNS disease with medical monitor approval. * Laboratory values outside the protocol-defined range at screening. * History or evidence of bleeding disorder or active clinically significant bleeding requiring medical intervention.
References
Publications (0)
Data not yet available
No reference posted for this study.